Loading...
•
Jun 30, 2022
Danimer Scientific Q2 2022 Earnings Report
Announced second quarter 2022 results.
Key Takeaways
Danimer Scientific reported revenues of $12.7 million for the second quarter, with PHA-based product sales increasing by 85% year-over-year. The company's net loss was $30.4 million, which included a $2.0 million non-cash gain from warrant remeasurement. They reaffirm Adjusted EBITDA to be in the range of $(45) million to $(35) million.
Revenues in the second quarter were $12.7 million.
PHA-based product sales were up 85% from the comparable period in the prior year, expanding to 61% of total revenue compared to 29% in the second quarter of 2021.
Gross profit was $(2.2) million compared to $2.0 million in the second quarter of 2021.
Net loss of $30.4 million included a $2.0 million non-cash gain related to the remeasurement of the Company’s private warrants for the second quarter of 2022.
Revenue by Segment
Forward Guidance
Danimer reaffirms its outlook for Adjusted EBITDA to be in the range of $(45) million to $(35) million, and now expects full year capital expenditures to be in the range of $175 million to $185 million, with a year-end cash balance in excess of $60 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...